The farnesyltransferase inhibitor, LB42708, inhibits growth and induces apoptosis irreversibly in H-ras and K-ras-transformed rat intestinal epithelial cells

Toxicology and Applied Pharmacology

Volumn 215, Issue 3, 2006, Pages 317-329

  Kim, Han Soo ^a   Kim, Ju Won ^a   Gang, Jingu ^a   Wen, Jing ^a   Koh, Sang Seok ^b   Koh, Jong Sung ^b   Chung, Hyun Ho ^b   Song, Si Young ^a  

^a Yonsei University College of Medicine   (South Korea)

^b LG Chemical Ltd   (South Korea)

Author keywords

Apoptosis; EGFR; FTI; MAPK; Prenylation; ras; RhoB

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1; EPIDERMAL GROWTH FACTOR RECEPTOR; LB 42708; LB 42908; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN FARNESYLTRANSFERASE INHIBITOR; RHOB GUANINE NUCLEOTIDE BINDING PROTEIN; STRESS ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CELL TRANSFORMATION; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME INHIBITION; GROWTH INHIBITION; INTESTINE EPITHELIUM CELL; NONHUMAN; ONCOGENE H RAS; ONCOGENE K RAS; PROTEIN EXPRESSION; RAT; UPREGULATION;

ANIMALS; APOPTOSIS; CELL CYCLE; CELL LINE, TRANSFORMED; CELL PROLIFERATION; CYCLIN-DEPENDENT KINASE INHIBITOR P21; ENZYME INHIBITORS; FARNESYLTRANSTRANSFERASE; GENES, RAS; IMIDAZOLES; INTESTINAL MUCOSA; PIPERAZINES; PYRROLES; RATS; RHOB GTP-BINDING PROTEIN;

EID: 33748144751     PISSN: 0041008X     EISSN: 10960333     Source Type: Journal    
DOI: 10.1016/j.taap.2006.03.011     Document Type: Article

References (55)

1. Agarwal M.L., Taylor W.R., Chernov M.V., Chernova O.B., and Stark G.R. The p53 network. J. Biol. Chem. 273 (1998) 1-4
2. Almoguera C., Shibata D., Forrester K., Martin J., Arnheim N., and Perucho M. Most human carcinoma of the exocrine pancreas contain mutant c-K-ras gene. Cell 53 (1988) 549-554
3. Ashar H.R., James L., Gray K., Carr D., Black S., Armstrong L., Bishop W.R., and Kirschmeier P. Farnesyl transferase inhibitors block he farnesylation of CENP-E and CENP-F and alter the association of CENP-E with microtubules. J. Biol. Chem. 275 (2000) 30451-30457
4. Bishop W.R., Kirschmeier P., and Baum C. Farnesyl transferase inhibitors: mechanism of action, translational studies and clinical evaluation. Cancer Biol. Ther. 2 Suppl. 1 (2003) 73-81
5. Bos J.L. Ras oncogenes in human cancer: a review. Cancer Res. 49 (1989) 4682-4689
6. Chou T., and Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv. Enzyme Regul. 22 (1984) 27-55
7. Cox A., and Der C. Farnesyltranferase inhibitors and cancer treatment targeting imply Ras?. Biophysica 1333 (1997) F51-F71
8. Du W., Lebowitz P.F., and Prendergast G.C. Cell growth inhibition by farnesyltransferase inhibitors is mediated by gain of geranylgeranylated RhoB. Mol. Cell. Biol. 19 (1999) 1831-1840
9. Efuet E.T., and Keyomarsi K. Farnesyl and geranylgeranyl transferase inhibitors induce G1 arrest by targeting the proteosome. Cancer Res. 66 (2006) 1040-1051
10. Fritz G., and Kaina B. rhoB encoding a UV-inducible Ras-related small GTP-binding protein is regulated by GTPases of the Rho family and independent of JNK, ERK, and p38 MAP kinase. J. Biol. Chem. 272 (1997) 30637-30644
11. Fritz G., Kaina B., and Aktories K. The ras-related small GTP-binding protein RhoB is immediate-early inducible by DNA damaging treatments. J. Biol. Chem. 270 (1995) 25172-25177
12. Gampel A., Parker P., and Mellor H. Regulation of epidermal growth factor receptor traffic by the small GTPase RhoB. Curr. Biol. 9 (1999) 955-958
13. Gangarosa L.M., Sizemore N., Graves-Deal R., Oldham S.M., Der C.J., and Coffey R.J. A raf-independent epidermal growth factor receptor autocrine loop is necessary for Ras transformation of rat intestinal epithelial cells. J. Biol. Chem. 272 (1997) 18926-18931
14. Garcia A.M., Rowell C., Ackermann K., Kowalczyk J.J., and Lewis M.D. Peptidomimetic inhibitors of Ras farnesylation and function in whole cells. J. Biol. Chem. 268 (1993) 18415-18418
15. Glomset J.A., and Farnsworth C.C. Role of protein modification reactions in programming interactions between ras-related GTPases and cell membranes. Annu. Rev. Cell Biol. 10 (1994) 181-205
16. Hou J., Li B., Yang Z., Fager N., and Ma M.Y.J. Altered gene activity of epidermal growth factor receptor (ErbB-1) in the hypothalamus of aging female rat is linked to abnormal estrous cycle. Endocrinol. 143 (2002) 577-586
17. Hou J., Li B., Yang Z., Fager N., and Ma M.Y.J. Functional integrity of ErbB-4/-2 tyrosine kinase receptor complex in the hypothalamus is required for maintaining normal reproduction in young adult female rats. Endocrinology 143 (2002) 1901-1912
18. James G.L., Goldstein J.L., Brown M.S., Rawson T.E., Somers T.C., and McDowell R.S. Benzodiazepine peptidomimetics: potent inhibitors of Ras farnesylation in animal cells. Science 260 (1993) 1937-1942
19. James G., Goldstein J.L., and Brown M.S. Resistance of K-RasB proteins to farnesyltransferase inhibitors in Rat1 cells. Proc. Natl. Acad. Sci. U.S.A. 93 (1996) 4454-4458
20. Jiang K., Delarue F.L., and Sebti S.M. EGFR, ErbB2 and Ras but not Src suppress RhoB expression while ectopic expression of RhoB antagonizes oncogene-mediated transformation. Oncogene 23 (2004) 1136-1145
21. Kohl N.E., Mosser S.D., deSolms S.J., Giyliani E.A., Pompliano D.L., Graham S.L., Smith R.L., Scolnick E.M., Oliff A., and Gibbs J.B. Selective inhibition of ras-dependent transformation by a farneysltransferase inhibitor. Science 260 (1993) 1934-1937
22. Kohl N.E., Wilson F.R., Mosser S.D., Giuliani E., deSolms S.J., Conner M.W., Anthony N.J., Holtz W.J., Gomez R.P., Lee T.J., Smith R.L., Graham S.L., Hartman G.D., Gibbs J.B., and Oliff A. Protein farnesyltransferase inhibitors block the growth of ras-dependent tumors in nude mice. Proc. Natl. Acad. Sci. U.S.A. 91 (1994) 9141-9145
23. Law B.K., Norgaard P., and Moses H.L. Farnesyltransferase inhibitor induces rapid growth arrest and blocks p70s6k activation by multiple stimuli. J. Biol. Chem. 275 (2000) 10796-10801
24. Lebowitz P.F., and Prendergast G.C. Non-Ras targets of farnesyltransferase inhibitors: focus on Rho. Oncogene 17 (1998) 1439-1445
25. Lebowitz P.F., Casey P.J., Prendergast G.C., and Thissen J.A. Farneyltransferase inhibitors alter the prenylation and growth-stimulating function of RhoB. J. Biol. Chem. 272 (1997) 15591-15594
26. Lee H., Lee J., Lee S., Shin Y., Jung W., Kim J.-H., Park K., Kim K., Cho H.S., Ro S., Lee S., Jeong S., Choi T., Chung H.-H., and Koh J.S. A novel class of highly potent, selective, and non-peptidic inhibitors of Ras farnesyltransferase (FTase). Bioorg. Med. Chem. Lett. 11 (2001) 3069-3072
27. Lee H., Lee J., Shin Y., Jung W., Kim J.-H., Park K., Ro S., Chung H.-H., and Koh J.S. 3-Aryl-4-aryloyl-1(1H-imidazol-5-yl)methylpyrrole, a novel class of farnesyltransferase inhibitors. Bioorg. Med. Chem. Lett. 11 (2001) 2963-2965
28. Lerner E.C., Zhang T.-T., Knowles D.B., Qian Y., Hamilton A.D., and Sebti S.M. Inhibition of the prenylation of K-Ras, but not H- or N-Ras, is highly resistant to CAAX peptidomimetics and requires both a farneyltransferase and a geranylgeranyltransferase I inhibitor in human tumor cell lines. Oncogene 15 (1997) 1283-1288
29. Liu M., Bryant M.S., Chen J., Lee S., Yaremko B., Lipari P., Malkowski M., Ferrari E., Nielsen L., Prioli N., Dell J., Sinha D., Syed J., Korfmacher W.A., Nomeir A.A., Lin C.-C., Wang L., Taveras A.G., Doll R.J., Njoroge F.G., Mallams A.K., Remiszewski S., Catino J.J., Girijacallabhan V.M., Kirschmeier P., and Bishop W.B. Antitumor activity of SCH 66336, an orally bioavailable tricyclic inhibitor of farnesyl protein transferase, in human tumor xenograft models and wap-ras tansgenic mice. Cancer Res. 58 (1998) 4947-4956
30. Liu A., Du W., Liu J.P., Jessell T.M., and Prendergast G.C. RhoB alteration is necessary for apoptotic and antineoplastic responses to farnesyltransferase inhibitors. Mol. Cell. Biol. 20 (2000) 6105-6113
31. Maddala R.L., Reddy V.N., and Rao P.V. Lovastatin-induced cytoskeletal reorganization in lens epithelial cells: role of Rho GTPase. Invest. Ophthalmol. Visual Sci. 42 (2001) 2610-2615
32. Mizukami Y., Ura H., Obara T., Habiro A., Izawa T., Osanai M., Yanagawa N., Tanno S., and Kohgo Y. Requirement of c-jun N-terminal kinase for apoptotic cell death induced by farnesyltransferase inhibitor, farnesylamine, in human pancreatic cancer cells. Biochem. Biophys. Res. Commun. 288 (2001) 198-204
33. Nelson M.A., Wymer J., and Clements Jr Jr. N. Detection of K-ras gene mutations in non-neoplastic lung tissue and lung cancers. Cancer Lett. 103 (1996) 115-121
34. Oldham S.M., Clark G.J., Gangarosa L.M., Coffey R.J., and Der C.J. Activation of the Raf-1/MAP kinase cascade is not sufficient for Ras transformation of RIE-1 epithelial cells. Proc. Natl. Acad. Sci. U.S.A. 93 (1996) 6924-6928
35. Oldham S.M., Cox A.D., Reynolds E.R., Sizemore N.S., Coffey R.J., and Der C. Ras, but not src, transformation of RIE-1 epithelial cells is dependent on activation of the mitogen-activated protein kinase cascade. Oncogene 16 (1998) 2565-2573
36. Oliff A. Farnesyltransferase inhibitors: targeting the molecular basis of cancer. Biochim. Biophys. Acta 1423 (1999) C19-C30
37. Prendergast G.C., Davide J.P., DeSolms S.J., Giuliani E.A., Graham S.L., Gibbs J.B., Oliff A., and Kohl N.E. Farnesyltransferase inhibition causes morphological reversion of ras-transformed cells by a complex mechanism that involves regulation of the actin cytoskeleton. Mol. Cell. Biol. 14 (1994) 4193-4202
38. Reuveni H., Klein S., and Levitzki A. The inhibition of Ras farnesylation leads to an increase in p27Kip1 and G1 cell cycle arrest. Eur. J. Biochem. 270 (2003) 2759-2772
39. Russo P., Ottoboni C., Crippa A., Riou J.-F., and O'Connor P.M. RPR-115135, a new non peptidomimetic farneyltransferase inhibitor, induces G0/G1 arrest only in serum starved cells. Int. J. Oncol. 18 (2001) 855-862
40. Shapiro G.I., Edwards D.F., and Rollins B.J. The physiology of p16(INK4A)-mediated G1 proliferative arrest. Cell Biochem. Biophys. 33 (2000) 189-197
41. Sherr C.J., and Roberts J.M. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev. 13 (1999) 1501-1512
42. Sizemore N., Cox A.D., Barnard J.A., Oldham S.M., Reynolds E.R., Der C.J., and Coffey R.J. Pharmacological inhibition of Ras-transformed epithelial cell growth is linked to down-regulation of epidermal growth factor-related peptides. Gastroenterology 117 (1999) 567-576
43. Smalley K.S.M., and Eisen T.G. Farnesyl transferase inhibitor SCH66336 is cytostatic, pro-apoptotic and enhances chemosensitivity to cisplatin in melanoma cells. Int. J. Cancer 105 (2003) 165-175
44. Smit V.T., Boot A.J., Smits A.M., Fleuren G.J., Cornelisse C.J., and Bos J.L. K-ras codon 12 mutations occur very frequently in pancreatic adenocarcinoma. Nucleic Acids Res. 16 (1988) 7773-7782
45. Song S.Y., Meszoely I.M., Coffey R.J., Pietenpol J.A., and Leach S.D. K-Ras-independent effects of the farnesyl transferase inhibitor L-744,832 on cyclin B1/Cdc2 kinase activity, G2/M cell cycle progression and apoptosis in human pancreatic ductal adenocarcinoma cells. Neoplasia 2 (2000) 1-12
46. Sun J., Qian Y., Hamilton A.D., and Sebti S.M. Both farnesyltransferase and geranylgeranyltransferase I inhibitors are required for inhibition of oncogenic K-Ras prenylation but each alone is sufficient to suppress human tumor growth in nude mouse xenografts. Oncogene 16 (1998) 1467-1473
47. van Golen K.L., Bao L.W., DiVito M.M., Wu Z.F., Prendergast G.C., and Merajver S.D. Reversion of RhoC GTPase-induced inflammatory breast cancer phenotype by treatment with a farnesyl transferase inhibitor. Mol. Cancer Ther. 1 (2002) 575-583
48. Villalonga P., Lopez-Alcala C., Chiloeches A., Gil J., Marais R., Bachs O., and Agell N. Calmodulin prevents activation of Ras by PKC in 3T3 fibroblasts. J. Biol. Chem. 277 (2002) 37929-37935
49. Wherlock M., Gampel A., Futter C., and Mellor H. Farnesyltransferase inhibitors disrupt EGF receptor traffic through modulation of the RhoB GTPase. J. Cell Sci. 117 (2004) 3221-3231
50. Whyte D.B., Kirischmeier P., Hockenberry T.N., Nunez-Olivia I., James L., and Catino J.J. K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors. J. Biol. Chem. 272 (1997) 14459-14464
51. Yamagata K., Sanders L.K., Kaufmann W.E., Yee W., Barnes C.A., Nathans D., and Worley P.F. rheb, a growth factor- and synaptic activity-regulated gene, encodes a novel Ras-related protein. J. Biol. Chem. 269 (1994) 16333-16339
52. Zeng P.-Y., Rane N., Du W., Chintapalli J., and Prendergast G.C. Role for RhoB and PRK in the suppression of epithelial cell transformation by farnesyltransferase inhibitors. Oncogene 22 (2003) 1124-1134
53. Zhang F.L., and Casey P.J. Protein prenylation: molecular mechanisms and functional consequences. Annu. Rev. Biochem. 65 (1996) 241-269
54. Zieske J.D., Takahashi H., Hutcheon A.E.K., and Dalbone A.C. Activation of epidermal growth factor receptor during corneal epithelial migration. Invest. Ophthalmol. Visual Sci. 41 (2000) 1346-1355
55. Zohn I.M., Campbell S.L., Khosravi-Far R., Rossman K.L., and Der C.J. Rho family proteins and Ras transformation: the RHOad less traveled gets congested. Oncogene 17 (1998) 1415-1438